Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis

European Journal of Haematology

Volumn 72, Issue 4, 2004, Pages 239-244

  Bock, Oliver ^a   Neusch, Michael ^a   Büsche, Guntram ^a   Mengel, Michael ^a   Kreipe, Hans ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bone marrow cells; FK506 binding protein 51; Idiopathic myelofibrosis; Laser microdissection; Megakaryocytes; Real time RT PCR

Indexed keywords

CD34 ANTIGEN; COMPLEMENTARY DNA; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMUNOHISTOCHEMISTRY; MALE; MEGAKARYOCYTE; MYELOFIBROSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL NUCLEUS; CYTOPLASM; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HUMANS; MALE; MEGAKARYOCYTES; MIDDLE AGED; MYELOFIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TACROLIMUS BINDING PROTEINS;

EID: 1642442672     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00204.x     Document Type: Article

References (15)

1. BAUGHMAN G, WIEDERRECHT GJ, CAMPBELL NF, MARTIN MM, BOURGEOIS S. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 1995;15:4395-4402.
2. NAIR SC, RIMERMAN RA, TORAN EJ, CHEN S, PRAPAPANICH V, BUTTS RN, SMITH DF. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol Cell Biol 1997;17:594-603.
3. TEFFERI A. Chronic myeloid disorders: classification and treatment overview. Sem Hematol 2001;38(Suppl. 2):1-4.
4. RABELLINO EM, LEVENE RB, NACHMAN RL, LEUNG LL. Human megakaryocytes. III. Characterization in myeloproliferative disorders. Blood 1984;63:615-622.
5. GIRAUDIER S, CHAGRAOUI H, KOMURA E et al. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 2002;100:2932-2940.
6. BOCK O, KREIPE H, LEHMANN U. One-step extraction of RNA from archival biopsies. Anal Biochem 2001;295:116-117.
7. SCHUTZE K, LAHR G. Identification of expressed genes by laser-mediated manipulation of single cells. Nat Biotechnol 1998;16:737-742.
8. BOCK O, SCHLUÉ J, LEHMANN U, VON WASIELEWSKI R, LÄNGER F, KREIPE H. Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression. Blood 2002;100:2274-2275.
9. BOCK O, LEHMANN U, KREIPE H. Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia. J Mol Diagn 2003;5:54-60.
10. LIVAK KJ, SCHMITTGEN TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
11. MENGEL M, KREIPE H, VON WASIELEWSKI R. Rapid and large-scale transition of new tumor biomarkers to clinical biopsy material by innovative tissue microarray systems. Appl Immunohistochem Mol Morphol 2003;11:261-268.
12. CLIPSTONE NA, CRABTREE GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-697.
13. KOMURA E, CHAGRAOUI H, MANSAT DE MAS V et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp Hematol 2003;31:622-630.
14. DAVIES TH, NING YM, SANCHEZ ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 2002;277:4597-4600.
15. VERMEER H, HENDRIKS-STEGEMAN BI, VAN DER BURG B, VAN BUUL-OFFERS SC, JANSEN M. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metabol 2003;88:277-284.